How Prior Authorization Failures Are Costing Dermatology Clinics Thousands in Lost Revenue

Free Demo

$83,200 avg. annual revenue lost per dermatology practice from PA denials

17 days average delay before a biologic therapy PA gets approved

1 in 3 prior auth requests in dermatology are initially denied

It starts with a phone call. A patient with moderate-to-severe psoriasis calls to ask why their biologic prescription hasn't been approved yet. They were told two weeks ago that authorization was submitted. Their disease is flaring. They're frustrated. And honestly? Your front desk team is frustrated too, because this is the third time this month they've had to track down a prior authorization that fell somewhere between your office and the payer.

Meanwhile, somewhere in your revenue cycle, that claim and a handful of others just like it is quietly becoming a write-off.

Prior authorization failures are one of the most underestimated revenue drains in dermatology. They don't announce themselves with a loud denial letter the way a coding error does. Instead, they erode your practice's financial health slowly and steadily: through delayed approvals, abandoned claims, appeals that take longer than the original submission, and patients who after waiting too long simply stop pursuing treatment.

The real cost of prior authorization failures isn't just the denied claim. It's everything that happens around it — the staff hours, the patient relationships, and the downstream revenue that quietly disappears.

This article is about where those failures actually happen, why dermatology practices are disproportionately exposed to them, and what the practices managing this well are doing differently.

What Prior Authorization Really Means in a Dermatology Practice

Prior authorization the requirement that a provider obtain payer approval before delivering a service or prescribing a medication isn't new. But in dermatology, it has become one of the most administratively intensive and financially consequential parts of running a practice.

The reason dermatology is so heavily affected comes down to the nature of the specialty. You're managing chronic inflammatory conditions that require expensive specialty medications. You're performing procedures that payers often classify as potentially cosmetic. And you're dealing with a patient population where treatment delays don't just mean inconvenience they mean disease progression, worsening quality of life, and sometimes significant clinical consequences.

Each of these categories comes with its own documentation requirements, its own payer-specific rules, and its own appeal pathway when the initial request fails. Managing this across a full patient panel with multiple payers, each operating under different criteria is a significant operational challenge that most practices weren't originally built to handle at this scale.

Where Failures Actually Happen — And Why They Keep Repeating

Here's the thing about prior authorization failures: they rarely happen for one reason. They happen because several small process gaps compound on each other in ways that aren't visible until a claim gets denied or a patient calls upset.

In most dermatology practices, the problem starts when the authorization process is treated as a one-time submission task rather than a managed workflow. Someone submits the request, assumes it's being processed, and moves on — without tracking status, confirming receipt, or preparing for the follow-up steps that many payers require before approving.

01	Incomplete or Inadequate Medical Necessity Documentation
?	Root Cause:  Payers require condition-specific clinical evidence to approve dermatology services. For biologics, that means documented disease severity scores (PASI, BSA, IGA), failed conventional therapy records, and diagnosis-specific ICD-10 codes that match their coverage criteria. When chart notes are vague, generic, or don't explicitly state what the payer's criteria require, authorization is denied.
!	Impact:  This is the leading cause of first-pass PA denials in dermatology. The clinical work is done — the problem is that documentation doesn't translate it into the language payers require. Each failed request adds 2–4 weeks of delay and triggers an appeal cycle that consumes 30–60 minutes of staff time.
✔	The Fix:  Build payer-specific documentation templates for each major biologic and procedure category. Templates should prompt for required elements — disease severity scores, prior treatment history, relevant lab values, and diagnosis confirmation — at the point of note completion. Match ICD-10 codes to the payer's exact coverage criteria, not generic equivalents.

02	Step Therapy Requirements Not Met or Not Documented
?	Root Cause:  Most payers require proof that a patient tried and failed lower-cost treatment options before approving specialty medications or advanced procedures. For a biologic like Dupixent, that typically means documented trials of topical steroids, topical calcineurin inhibitors, and sometimes oral immunosuppressants. When that trail isn't clearly captured in the chart, the authorization fails.
!	Impact:  Step therapy documentation gaps are responsible for a substantial portion of biologic PA denials. The patient may have genuinely failed those treatments — but if the chart doesn't document it in a way the payer can verify, the authorization is denied as if the steps were never taken. Appeals are possible but add weeks to an already-delayed process.
✔	The Fix:  Create a structured step therapy tracking log within your EHR for patients likely to need specialty medications. Document each treatment trial with start date, duration, response, and reason for discontinuation. When submitting PA, include this history explicitly — don't assume the payer will infer it from the overall chart.

03	Coding Mismatches Between ICD-10 and CPT Codes
?	Root Cause:  Payers cross-reference diagnosis codes against the specific service being authorized. When the ICD-10 used doesn't match their coverage mapping for that CPT code — or when a general code is used where a specific one is required — the authorization request fails automatically. Common examples: using L40.0 (plaque psoriasis) when the payer's biologic criteria require L40.50 or L40.9 for joint involvement, or using a generic eczema code when the payer's Dupixent criteria require confirmed atopic dermatitis (L20.x).
!	Impact:  Automated payer systems reject authorization requests that fail code-matching edits before a human reviewer ever sees the clinical documentation. A single digit's difference in an ICD-10 code can mean the difference between approval and denial. These errors often go unnoticed because the denial reason is coded generically.
✔	The Fix:  Maintain an updated payer-specific code mapping reference for your top PA service categories. Review ICD-10 specificity requirements for each payer annually — they change. Incorporate a coding verification step into the PA submission workflow so requests don't go out on generic codes when specific ones are required.

04	Delayed Submissions and Expired Authorizations
?	Root Cause:  Authorization requests submitted after service has already been delivered, or services rendered after a prior authorization has expired without renewal. Also includes situations where authorization was approved for a specific date range and the patient's appointment was rescheduled outside that window — without anyone updating the authorization.
!	Impact:  Retroactive authorization requests are denied almost universally. Services delivered on an expired authorization generate claims that fail on submission — creating non-billable encounters and patient balance-billing complications. Authorization expiration is one of the most common and most preventable causes of claim denials in high-volume dermatology practices.
✔	The Fix:  Implement a centralized PA tracking system that captures approval dates, expiration dates, and scheduled service dates for every authorized service. Build 30-day and 60-day renewal alerts. Include authorization status in the appointment confirmation workflow — no procedure appointment should be finalized without a confirmed, current authorization on file.

05	Payer-Specific Rule Variations Not Followed
?	Root Cause:  Medicare, Medicaid, and commercial payers each have different authorization requirements for the same service — different forms, different clinical criteria, different appeal timelines, and different preferred submission channels. A process that works seamlessly with Blue Cross fails with Aetna for the same biologic, not because the clinical case is different but because the payer's requirements are.
!	Impact:  When a single authorization workflow is applied across all payers, it consistently fails at the points where payer-specific requirements diverge. Staff submit what they believe to be a complete request, it fails for a payer-specific reason that wasn't anticipated, and the resulting denial is chalked up to 'payer complexity' rather than a workflow gap. This pattern repeats indefinitely.
✔	The Fix:  Build a payer-specific PA reference guide covering your top five payers for each major service category. Document preferred submission channels, required forms, clinical criteria differences, and appeal deadlines. Assign ownership of payer updates to a specific role so the guide stays current. Treat payer-specific requirements as non-negotiable inputs to your workflow, not optional nuances.

The Real Financial Impact on Your Practice

Put the operational frustration aside for a moment and look at what prior authorization failures actually cost in terms you can trace on a P&L.

$14.50 average staff cost per prior authorization submission (MGMA)

$36–72 cost to rework a denied PA through appeal

43% of abandoned PA requests are never resubmitted

The number that doesn't appear on any report: the revenue that was never generated because a treatment was abandoned before it started. Denied PAs that never get appealed, patients who gave up after a second delay, biologics that were prescribed but never approved this is the silent leakage that most practices have no mechanism to track, which means they have no way to know how large it actually is.

The Hidden Costs Most Dermatology Clinics Never Calculate

Beyond the directly trackable denial revenue, there's a layer of costs that don't show up in billing reports but are very real to everyone who works in your practice.

What's Really Being Consumed by PA Management Failures

⚠     Physician bandwidth: Peer-to-peer review calls, appeal letters, and authorization justification documentation pull physicians out of clinical care. For practices managing 50+ active biologic patients, this can represent 2–4 hours per week of uncompensated administrative work.

⚠     Staff burnout and turnover: Prior authorization management is among the most cited sources of medical billing staff frustration. Teams dealing with high PA failure rates, repeated payer follow-up calls, and unresolved denials experience burnout at higher rates — and turnover in billing staff is expensive, typically costing $10,000–$20,000 per position to replace.

⚠     Patient experience damage: Patients associate authorization delays with your practice, not the payer. When a patient calls three times to ask why their treatment hasn't been approved, their confidence in your practice erodes — even when the delay is entirely the payer's doing. That relationship damage is real and sometimes permanent.

⚠     Compliance exposure: Billing for services before authorization is confirmed — even unintentionally, when staff believe authorization was obtained — creates retroactive denial and potential overpayment liability. In practices with poor PA tracking, this happens more often than anyone realizes.

Why Dermatology Carries Higher Prior Authorization Risk Than Most Specialties

Prior authorization is a burden across all of medicine, but dermatology has several characteristics that make it particularly exposed to PA failures and their downstream consequences.

What many dermatology practices don't realize is that this combination of factors high-cost specialty medications, ambiguous cosmetic/medical distinctions, and complex step therapy requirements puts their PA approval rates at the bottom of specialty comparisons. Dermatology consistently sees higher first-pass denial rates than primary care, cardiology, or even oncology for most service categories.

A payer that can find a documentation gap, a step therapy shortfall, or a code mismatch will use it. In dermatology, there's rarely a shortage of opportunities to look.

What Dermatology Practices With Low PA Failure Rates Are Doing

The practices consistently achieving first-pass authorization approval rates above 85% aren't doing anything extraordinary. They've just built workflows that treat prior authorization as a managed, trackable process rather than an administrative task that gets delegated and forgotten.

Six Workflow Differences in Practices That Win on Prior Auth

1.     Dedicated PA coordination role. In high-performing dermatology practices, prior authorization isn't a shared responsibility that falls on whoever has time. It's a designated function with specific ownership, accountability metrics, and expertise in payer-specific requirements.

2.     Payer-specific submission templates. Rather than submitting the same documentation package to every payer, these practices maintain updated templates for each major payer's requirements for each major service category. When a Dupixent authorization goes to Aetna, it's built to Aetna's criteria. When it goes to United, it's built to United's criteria.

3.     Pre-authorization eligibility verification. Before a PA request is submitted, these practices verify that the patient's current plan covers the service, confirm current authorization requirements, and check for any payer-side changes that affect the submission. Nothing goes out based on assumptions from a previous submission.

4.     Structured step therapy documentation from visit one. For patients likely to need biologic therapy, documentation of conventional treatment trials begins at the first visit — not when the PA request is being assembled. By the time authorization is needed, the step therapy record is already complete and organized.

5.     Active denial tracking and root-cause analysis. Every denied PA is categorized by reason, payer, and service type. Patterns are identified and addressed — not by resubmitting the same request hoping for a different outcome, but by understanding why the denial happened and fixing the upstream documentation or coding issue.

6.     Strategic use of specialty billing expertise. Many practices reaching high approval rates have outsourced or co-managed their PA workflow with billing partners who specialize in dermatology revenue cycle management. The depth of payer-specific knowledge required to consistently win on prior authorization is difficult to maintain in-house without dedicated resources.

A Smarter Way to Manage Prior Authorization in Dermatology

There's a growing shift in how dermatology practices are approaching this problem. Rather than continuing to absorb the cost of PA failures — training internal staff, managing payer-specific complexity in-house, and rebuilding processes after every personnel change — more practices are partnering with billing teams that specialize in dermatology revenue cycle management.

The case for this shift is straightforward. Prior authorization in dermatology requires current knowledge of payer-specific criteria for dozens of biologics and specialty medications, familiarity with step therapy documentation standards, experience with peer-to-peer review processes, and awareness of payer policy changes as they happen. That's a significant knowledge base to maintain internally, and it's one that degrades quickly when experienced staff turn over.

Partnering with a dermatology billing specialist doesn't mean losing control of your clinical decisions or your patient relationships. It means giving the administrative side of prior authorization the specialized attention it requires — so your team can focus on care delivery rather than payer management.

What well-positioned practices report: reduced denial rates, faster average approval timelines, less physician time spent on administrative escalations, and improved cash flow predictability. The return on investment isn't theoretical — it shows up in monthly collections within 60–90 days of optimizing the PA workflow.

The Reality for Dermatology Billing in the Years Ahead

Payer scrutiny of dermatology services isn't going to ease. The biologics pipeline continues to expand. New indications are approved. Coverage criteria are updated. Authorization requirements for existing medications get more specific over time, not less.

Practices that continue managing prior authorization as an afterthought — submitting requests and hoping for approval, rebuilding after staff turnover, treating denials as one-offs rather than patterns — will continue losing revenue they've earned and delaying care their patients need.

The practices that recognize this as a manageable operational problem — one that responds to the right workflows, the right expertise, and the right performance tracking — will have a meaningful advantage in practice economics as this environment continues to evolve.

Three Questions Worth Asking About Your Practice Right Now

1.     Do you know your current first-pass PA approval rate? If you can't answer this question within a day, you don't have enough visibility into one of your practice's most significant revenue variables.

2.     How many PA denials from the past 90 days were never appealed? These represent finalized revenue losses that were avoidable. The pattern tells you how much your current process is costing.

3.     What percentage of your biologic patients have an active, current authorization? Expiration gaps in your authorization portfolio are future denials that haven't been submitted yet. Finding them now costs far less than fixing them after the claim fails.

If these questions don't have clear, confident answers — or if the answers reveal gaps you already suspected — that's not a reason for alarm. It's a reason to have a real conversation about what a better prior authorization workflow would look like for your practice.

Find Out What PA Failures Are Costing Your Practice

We offer a complimentary dermatology billing review — an honest look at your prior authorization denial patterns, revenue leakage, and workflow gaps. No obligation. No jargon. Just clarity on where the money is going.

»  Schedule Your Free Review →  siriussolutionsglobal.com

The patients waiting on authorization approvals deserve better. Your practice's revenue deserves better. And the staff managing this process every day definitely deserves better. A smarter prior authorization workflow is a solvable problem — and most practices that address it directly see measurable improvement within a single billing cycle.

Prior authorization failures are not an unavoidable cost of running a dermatology practice. They are a process problem — and process problems have solutions.

Free Demo

Dermatology Billing Services  |  Revenue Cycle Management

Prior Authorization Management  |  Denial Prevention  |  Claims Optimization

Specialty expertise. Faster approvals. Revenue you can count on.